Formulation and Device Lifecycle Management of Biotherapeutics
A Guidance for Researchers and Drug Developers
- 1st Edition - January 14, 2022
- Imprint: Academic Press
- Authors: Beate Bittner, Johannes Schmidt
- Language: English
- Paperback ISBN:9 7 8 - 0 - 1 2 - 8 2 3 7 4 1 - 0
- eBook ISBN:9 7 8 - 0 - 1 2 - 8 2 3 7 4 2 - 7
Today, the pressure on healthcare costs and resources is increasing, and especially for biopharmaceuticals that require parenteral administration, the inherent complex and in… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteToday, the pressure on healthcare costs and resources is increasing, and especially for biopharmaceuticals that require parenteral administration, the inherent complex and invasive dosing procedure adds to the demand for efficient medical management. In light of the COVID-19 pandemic the value of drug delivery technologies in enabling a flexible care setting is broadly recognized. In such a setting, patients and their caregivers can choose the place of drug administration based on individual preferences and capabilities. This includes not only dosing in the clinic but also supervised at-home dosing and self-administration for eligible patients.
Formulation and Device Lifecycle Management of Biotherapeutics: A Guidance for Researchers and Drug Developers
covers the various aspects of improving drug delivery of biological medicines with the ultimate goal to reduce dosing complexity associated with parenteral administration and, thus, enhance patient experience and drug administration-related healthcare capacity. The target audience are multidisciplinary researchers and drug developers in the pharmaceutical industry, biotech companies, and academia involved in formulation and device development. This includes pharmacology and medical experts in charge of generating nonclinical and clinical data to support approval of novel dosing regimens, and drug delivery scientists and engineers responsible for technical particulars of product optimizations. Moreover, professionals in market access and commercial functions are expected to benefit from the discussions about the impact of patient and healthcare provider needs and country-specific reimbursement models on realizing a truly convenient and cost and resource efficient drug delivery solution.- Summarizes formulation and device lifecycle management activities that enable customer-centric and sustainable drug delivery for biotherapeutics
- Describes the pharmacokinetic-based clinical development pathway for subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies
- Details established clinical development pathways supporting the approval of automated subcutaneous injection devices and proposes novel concepts
- Discusses how to realize home- and self-administration of biotherapeutics in cancer care
- Highlights aspects of multidisciplinary formulation and device lifecycle management that can be leveraged across different disease areas and introduces a decision architecture on when and how drug developers should embark into related development activities
Researchers, drug developers and product strategy managers in the Pharmaceutical Industry, Biotech or Academia including in drug delivery, clinical and nonclinical pharmacology, and device technologies. Clinical Pharmacology students and professionals; Health Economics and Outcomes Research students and professionals and Professionals and students in technical functions
- Cover image
- Title page
- Table of Contents
- Copyright
- Introduction
- Chapter 1. Enabling customer-centric and sustainable drug delivery— formulation and device lifecycle management of biotherapeutics
- Abstract
- Introduction
- Impact of formulation and device lifecycle management opportunities for biotherapeutics
- Timing of formulation and device lifecycle management
- Technology platform approaches
- Key aspects that define the value of drug delivery improvements
- Summary and outlook
- References
- Chapter 2. Clinical development of subcutaneous dosing alternatives to established intravenous formulations for monoclonal antibodies—pharmacokinetic-based bridging approach
- Abstract
- Introduction
- Clinical bridging approaches from established intravenous to subcutaneous administration
- Clinical bridging programs for the subcutaneous formulations of trastuzumab and rituximab
- Summary and future perspectives
- References
- Chapter 3. Clinical development of automated subcutaneous injection devices—established pathways and novel concepts
- Abstract
- Introduction
- Usability and pharmacokinetic comparability studies for biologic–device combination products
- Conceptual clinical bridging approach for device technology platforms
- Summary and outlook
- References
- Chapter 4. Enabling a flexible care setting in oncology—how to realize home- and self-administration of biotherapeutics in cancer care
- Abstract
- Introduction
- The importance of simplifying drug delivery of biotherapeutics in oncology
- How to unfold the full value of a flexible care setting in cancer care?
- Home-administration of biologics in oncology—the regulatory perspective
- Summary and outlook
- References
- Chapter 5. Formulation and device lifecycle management of biotherapeutics—leveraging synergies across therapeutic areas
- Abstract
- Introduction
- Leveraging cross-indication and cross-product synergies to accelerate formulation and device lifecycle management
- Summary and conclusion
- References
- Chapter 6. Formulation and device lifecycle management of biotherapeutics—decision architecture
- Abstract
- Introduction
- Why should manufacturers embark into formulation and device lifecycle management?
- When to embark into formulation and device lifecycle management—general considerations
- When to embark into formulation and device lifecycle management—subcutaneous dosing alternative as a case study
- Summary and conclusions
- References
- Chapter 7. Summary and outlook
- Abstract
- Summary
- Discussion
- Index
- Edition: 1
- Published: January 14, 2022
- Imprint: Academic Press
- No. of pages: 228
- Language: English
- Paperback ISBN: 9780128237410
- eBook ISBN: 9780128237427
BB
Beate Bittner
Dr. Beate Bittner (Formulation and Device Franchise Leader, F. Hoffmann—La Roche) is a Pharmacist, and holds a PhD in Pharmaceutical Technology and Biopharmaceutics and Diploma in European Market Access. She has work experience as a Laboratory Head (Preformulation), Drug Metabolism and Pharmacokinetics Project Leader, Clinical Pharmacologist, Early Research and Development Project Leader, Clinical Team Leader, Global Development Team Leader, Product Optimization Director, and Senior Portfolio Strategy Director in enabling science-based strategic decision-making across all phases of drug discovery, development, and commercialization and in leading global strategic initiatives, clinical and cross-functional development, and project teams. Her major focus was on expanding access to medicines through optimized drug delivery. She also worked as a lecturer in pharmacology, developing new drugs and personalized healthcare (Baden-Wuertemberg Cooperative State University). Dr. Beate Bittner has more than 45 scientific publications and review articles in her name covering formulation and device lifecycle management.
Affiliations and expertise
Formulation and Device Franchise Leader, F. Hoffmann – La Roche, Basel, SwitzerlandJS
Johannes Schmidt
Dr. Johannes Schmidt (Global Head Product Optimization, F. Hoffmann—La Roche) is a Chemist, and holds a PhD in Organic Chemistry and Diploma in Pharmaceutical Medicine Development. He has work experience as a Laboratory Head (Analytics), Technical Development Leader, Early Research and Development Project Leader, Clinical Team Leader, and Lifecycle Leader in leading both small molecule and biotherapeutic programs in all phases of drug development and commercialization across multiple therapeutic areas, in guiding establishment of customer-centric target product profiles and implementation of innovative development strategies to maximize patient access; and in guiding strategic initiatives and multifunctional project teams related to formulation and device lifecycle management. His major focus was on maximizing product differentiation and patient access to medicines.
Affiliations and expertise
Global Head Product Optimization, F. Hoffmann – La Roche, Basel, SwitzerlandRead Formulation and Device Lifecycle Management of Biotherapeutics on ScienceDirect